Proven solutions exist now which could transform the efficiency, effectiveness and regulatory adherence of PV processes, without placing data at any risk of being compromised in any way. By John Price – Pharmacovigilance expert and advisor to Arriello.

Alan White, CEO of Arriello, explores alternative ways for life sciences firms to keep hold of experienced, qualified professionals as demand for pharmacovigilance skills soars.

Never previously at the forefront of technology innovation, the life sciences industry now accepts that it needs to transform its agility, responsiveness and cost-efficiency, and that advanced digital tools are likely to form an important part of that strategy. Advanced digital tools are certain to play a pivotal role in the redesign of labour-intensive regulatory processes, but there is a danger that AI's potential contribution is being over-hyped. Arriello's CEO Alan White warns that the key to ROI is in the application...

Merger & acquisition activity continues to be rife in life sciences, which is harming competition and reducing choice, both for patients and for more modest-sized pharma and biotech firms seeking help with growing pharmacovigilance and regulatory filing requirements. Alan White assesses the impact.